|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 17, 2017 ) Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.
Publisher's analysts forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.
For more information about this report: http://www.reportsweb.com/global-hemophilia-drugs-market-2016-2020
Covered in this report
The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Publisher's report, Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Baxalta
- Bayer
- CSL Behring
- Novo Nordisk
- Pfizer
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001438293/sample
Other prominent vendors
- Alnylam Pharmaceuticals
- Amarna Therapeutics
- Asklepios BioPharmaceutical
- Biogen
- BioMarin
- Catalyst Bioscience
- Chiesi Farmaceutici
- Dimension Therapeutics
- Emergent BioSolutions
- F. Hoffmann-La Roche
- Grifols, Kedrion Biopharma
- Octapharma
- rEVO Biologics
- OPKO Biologics
- Sangamo Biosciences
- Spark Therapeutics
- Swedish Orphan Biovitrum
- UniQure Biopharma.
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001438293/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
